Vicore Pharma Holding AB (publ) announced that the Phase 1 study of C106 has concluded and that Vicore will not continue further development due to a transient increase in blood pressure observed at doses believed to be in the clinically effective range. The Phase 1 study of C106 (NCT05427253), initiated in June 2022, was designed as a double-blind, placebo-controlled, randomized first-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of the drug candidate from 5 to 300 mg. While there were no major safety signals or tolerability concerns in the doses tested, an increase in blood pressure was observed at twice-daily doses of 140 mg and higher.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.4 SEK | -3.86% | +17.52% | +57.97% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.97% | 249M | |
+17.89% | 123B | |
+14.77% | 107B | |
-4.54% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.21% | 16.23B | |
+2.51% | 13.43B | |
+24.16% | 11.32B |
- Stock Market
- Equities
- VICO Stock
- News Vicore Pharma Holding AB
- Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106